Today at ADA 2021, ABCD is pleased to announce the launch of the ABCD nationwide oral semaglutide audit. As you will know, the clinical trials with semaglutide suggest that it may be more effective than the other GLP-1 receptor agonists. Results from the ABCD semaglutide audit, presented this weekend at ADA 2021, have demonstrated significant reductions in HbA1c and weight following commencement of semaglutide in a real-world cohort that was heavier with higher baseline HbA1c levels than those in clinical trials. Most interestingly, further reductions in HbA1c and weight occurred when switching from another GLP1-RA to semaglutide, although somewhat attenuated compared to the GLP1-RA naïve group. See:
Clinical trials with oral semaglutide suggest that it is also very effective compared to other available diabetes medications both in reducing HbA1c and weight. It is now of interest for us to find out the extent to which the experience in clinical trials translates into the real world.
Will there also be additional reductions in HbA1c and weight when switching from another GLP-1 receptor agonist to oral semaglutide?
For more information on the justification for the audit and the things we might find out see:
To register for the audit use this link:
You will be given access to the online tool. As we have done with previous audits all contributors will be acknowledged in all papers and presentations from the audit data and biggest contributors will be offered the possibility of being co-authors.
The tool will allow you to analyse the data of your own patients for your own local interest; at the same time the data will automatically be available for national analysis of anonymised data.
With best wishes on behalf of ABCD:
The ABCD nationwide oral semaglutide audit team:
Dr Tom Crabtree
Dr Barbara McGowan
Dr Karen Adamson
Dr Steve Bain
Dr Melanie Davies
Dr Bob Ryder